Literature DB >> 33320215

Changes in Outpatient Buprenorphine Dispensing During the COVID-19 Pandemic.

Jessica Duncan Cance1, Erin Doyle2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33320215      PMCID： PMC7739121          DOI： 10.1001/jama.2020.22154

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  2 in total

1.  Nonfatal Opioid Overdoses at an Urban Emergency Department During the COVID-19 Pandemic.

Authors:  Taylor A Ochalek; Kirk L Cumpston; Brandon K Wills; Tamas S Gal; F Gerard Moeller
Journal:  JAMA       Date:  2020-10-27       Impact factor: 56.272

2.  Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19.

Authors:  Corey S Davis; Elizabeth A Samuels
Journal:  Int J Drug Policy       Date:  2020-08-15
  2 in total
  9 in total

Review 1.  Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission.

Authors:  Keith Humphreys; Chelsea L Shover; Christina M Andrews; Amy S B Bohnert; Margaret L Brandeau; Jonathan P Caulkins; Jonathan H Chen; Mariano-Florentino Cuéllar; Yasmin L Hurd; David N Juurlink; Howard K Koh; Erin E Krebs; Anna Lembke; Sean C Mackey; Lisa Larrimore Ouellette; Brian Suffoletto; Christine Timko
Journal:  Lancet       Date:  2022-02-02       Impact factor: 202.731

2.  Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic.

Authors:  Alyssa Shell Tilhou; Laura Dague; Brendan Saloner; Daniel Beemon; Marguerite Burns
Journal:  JAMA Health Forum       Date:  2022-03-11

Review 3.  Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic.

Authors:  Jonathan Cantor; Andrew W Dick; Rebecca Haffajee; Megan F Pera; Dena M Bravata; Bradley D Stein; Christopher M Whaley
Journal:  J Subst Abuse Treat       Date:  2021-04-08

4.  Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID-19 pandemic in Kentucky.

Authors:  Feitong Lei; Michelle R Lofwall; Patricia R Freeman; Emily Slade; Rachel Vickers-Smith; Svetla Slavova
Journal:  J Rural Health       Date:  2022-05-24       Impact factor: 5.667

5.  Changes in the Care Activity in Addiction Centers with Dual Pathology Patients during the COVID-19 Pandemic.

Authors:  Cinta Mancheño-Velasco; Daniel Dacosta-Sánchez; Andrea Blanc-Molina; Marta Narvaez-Camargo; Óscar Martín Lozano-Rojas
Journal:  J Clin Med       Date:  2022-07-26       Impact factor: 4.964

6.  Changes in Buprenorphine and Methadone Supplies in the US During the COVID-19 Pandemic.

Authors:  Annie Y Chen; David Powell; Bradley D Stein
Journal:  JAMA Netw Open       Date:  2022-07-01

7.  A Qualitative Exploration of the Functional, Social, and Emotional Impacts of the COVID-19 Pandemic on People Who Use Drugs.

Authors:  Erin L Kelly; Megan K Reed; Kathryn M Schoenauer; Kelsey Smith; Kristina Scalia-Jackson; Sequoia Kay Hill; Erica Li; Lara Weinstein
Journal:  Int J Environ Res Public Health       Date:  2022-08-08       Impact factor: 4.614

8.  Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.

Authors:  Sophie A Kitchen; Tonya J Campbell; Siyu Men; Nikki Bozinoff; Mina Tadrous; Tony Antoniou; Jennifer Wyman; Dan Werb; Charlotte Munro; Tara Gomes
Journal:  Int J Drug Policy       Date:  2022-03-01

9.  Changes in Buprenorphine Prescribing to Medicaid Beneficiaries During the First Year of the COVID-19 Pandemic.

Authors:  William N Dowd; Tami L Mark
Journal:  JAMA Netw Open       Date:  2022-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.